XARMAPSII

REGENXBIO Inc.

Application Filed: 2023-09-25
Trademark Application Details
Trademark Logo XARMAPSII

Mark For: XARMAPSII™ trademark registration is intended to cover the categories of biological preparations for medical use; pharmaceutical preparations, namely, recombinant adeno-associated viral (rAAV) vectors for use in gene therapy; Pharmaceutical preparations for the treatment of genetic diseases and disorders and central nervous system (CNS) disorders, namely, neurodegenerative disorders; Pharmaceutical preparations for use in gene therapy; Clinical medical reagents for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders and neurodegenerative disorders; Therapeutic pharmaceutical compositions that include recombinant adeno-associated viral (rAAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy; Pharmaceutical preparations containing adeno-associated viral (AAV) vectors and nucleic acids for a system delivering genes to biological cells for use in the treatment of diseases, sicknesses, and disorders, namely, lysosomal storage disorders; gene therapy preparation containing genetic materials for sustained protein expression, namely, lysosomal enzyme expression.

Status

2024-02-21 UTC
LIVE APPLICATION Awaiting Examination
The trademark application has been accepted by the Office (has met the minimum filing requirements) and has not yet been assigned to an examiner.


Research OneLook Acronym Finder
Serial Number98196234
Mark Literal ElementsXARMAPSII
Mark Drawing Type4 - STANDARD CHARACTER MARK
Mark TypeTrademark
Current LocationNEW APPLICATION PROCESSING 2023-09-28
Basis1(b)
Class StatusACTIVE
Primary US Classes
  • 005: Adhesives
  • 006: Chemicals and Chemical Compositions
  • 018: Medicines and Pharmaceutical Preparations
  • 044: Dental, Medical and Surgical Appliances
  • 046: Foods and Ingredients of Foods
  • 051: Cosmetics and Toilet Preparations
  • 052: Detergents and Soaps
Primary International Class
  • 005 - Primary Class
  • (Pharmaceuticals) Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
Filed UseNo
Current UseNo
Intent To UseYes
Filed ITUYes
44D FiledNo
44E CurrentNo
66A CurrentNo
Current BasisNo
No BasisNo
Attorney NameWilliam R. Samuels
Attorney Docket Number1959.23

Timeline

2023-09-25Application Filed
2023-09-28Location: NEW APPLICATION PROCESSING
2023-09-28Status: Live/Pending
2023-09-28Status: New application awaiting assignment to an examining attorney. See current trademark processing wait times for more information.
2023-09-28Transaction Date

Trademark Parties (Applicants & Owners)

Party: REGENXBIO Inc.
Address9804 Medical Center Drive Rockville, MARYLAND UNITED STATES 20850
Legal Entity TypeCorporation
Legal Entity StateMARYLAND

Documents

Application2023-09-25
Drawing2023-09-25

Attorney of Record

WILLIAM R. SAMUELS
COLE-FRIEMAN & MALLON LLP
575 LEXINGTON AVENUE, 7TH FLOOR
NEW YORK, NY 10022

Good, Services, and Codes

International Codes:5
U.S. Codes:005,006,018,044,046,051,052
Type CodeType
GS0051Biological preparations for medical use; pharmaceutical preparations, namely, recombinant adeno-associated viral (rAAV) vectors for use in gene therapy; Pharmaceutical preparations for the treatment of genetic diseases and disorders and central nervous system (CNS) disorders, namely neurodegenerative disorders; Pharmaceutical preparations for use in gene therapy; Clinical medical reagents for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders and neurodegenerative disorders; Therapeutic pharmaceutical compositions that include recombinant adeno-associated viral (rAAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy; Pharmaceutical preparations containing adeno-associated viral (AAV) vectors and nucleic acids for a system delivering genes to biological cells for use in the treatment of diseases, sicknesses, and disorders, namely, lysosomal storage disorders; gene therapy preparation containing genetic materials for sustained protein expression, namely lysosomal enzyme expression

Trademark Filing History

DescriptionDateProceeding Number
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED2023-10-10
NEW APPLICATION ENTERED2023-09-28

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed